Plans to Remove Potentially Carcinogenic Contaminants from Januvia, Janumet Outlined By Merck
Merck indicates it will remove nitrosamine contaminants from Januvia and Janumet by the end of 2023.
Merck indicates it will remove nitrosamine contaminants from Januvia and Janumet by the end of 2023.
A federal judge has cleared Valsartan NDMA lawsuits to proceed after rejecting a call by defendants to reconsider the admissibility of plaintiffs' expert witnesses following the recent dismissal of Zantac…
An FDA inspection of the independent testing lab Valisure's former pharmacy division found it failed to identify illegitimate drug products and raised questions about the company's knowledge of the Food,…
Side effects of recalled valsartan may increase the risk of cancer, due to an impurity discovered in certain generic versions of the hypertension drug.
Some batches of Januvia, a diabetes drug, contain high levels of nitrosamines which could increase cancer risks, the FDA warns.
Pfizer is recalling five lots of Accupril, a hypertension drug, due to the risk of nitrosamine contamination and long-term cancer risk.
Pfizer is recalling several lots of Accuretic hypertension drugs due to the presence of potentially cancer-causing chemicals.
Two former district judges have been appointed as valsartan settlement special masters to help bring about a resolution to the litigation.
Canadian health regulators have announced an Accuretic recall, indicating the Pfizer hypertension drug contains levels of cancer-causing chemicals above the acceptable amounts.
Valsartan and similar hypertension drugs may carry an increased risk of cancer with long-term use, according to the findings of a new study.